Patents Assigned to Hoffman-La Roche Inc.
  • Patent number: 10846848
    Abstract: An image processing system configured to receive a first fluorescence image generically indicating the presence of biological matter; transform the first image into a transformed first image having a first color; for each of the biomarkers, receive a respective second fluorescence image indicating signals emitted by fluorescence stain selectively staining the biomarker, transforming the second images into a respective transformed second images having a respective second color; overlaying and combining the transformed first and second images; storing and/or displaying the combined image as the simulated digital bright field IHC or ISH image. The first image is created using an autofluorescence reference spectrum of the tissue sample or of a similar tissue sample or by using a fluorescence reference spectrum of a first stain which generically binds to biological matter of the tissue sample for spectrally unmixing of a multi-spectral digital image of the tissue sample.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 24, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventor: Eldad Klaiman
  • Patent number: 10837042
    Abstract: Herein is reported a feed mixing device for adding feed solutions with a non-physiologically pH value to a cell cultivation vessel comprising a chamber for mixing the feed solutions prior to their addition to the cell cultivation vessel as well as its use. With the feed mixing device as reported herein feed components can be provided in solution at a pH value at which they have good solubility and/or good stability whereby the pH value can be clearly different from the pH value of the cultivation medium, i.e. different from the physiological pH value. This allows performing the cultivation with more flexibility compared to a cultivation in which the pH value of the feed solution is limited to a small range around the pH value of the cultivation.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 17, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Sylvia Baumann, Jens Hoffmann, Alexander Jockwer, Christian Klinger, Thomas Troebs
  • Patent number: 10829555
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: November 10, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Patent number: 10825195
    Abstract: An image analysis method for analyzing an IHC tissue sample includes storing, for each of one or more sets of digital images, a set-ID in a spatial database of a spatial DBMS, the images of each set depicting the same or adjacent layers of the IHC tissue sample; storing, for each of the, a plurality of spatial data objects in the database in association with the set-ID; creating, by the spatial DBMS, at least one spatial index covering the objects of the images contained in the one or more sets; applying, by the spatial DBMS, a spatial database operation on the at least one spatial index for determining the relative positions of objects of two or more images of a selected set; and providing the relative positions as input for determining the distance and/or relative position of the biomedical features of the tissue sample.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: November 3, 2020
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Franziska Mech, Angelika Fuchs, Jan Kuentzer, Otto Huber, Alex Kohn, Eckhart Guthoehrlein
  • Patent number: 10800786
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: October 13, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Patrizio Mattei, Jerome Hert, Daniel Hunziker, Markus Rudolph, Petra Schmitz, Patrick Di Giorgio
  • Patent number: 10723762
    Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 28, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Patent number: 10718753
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: July 21, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Patent number: 10702800
    Abstract: Separating apparatus, comprising a sedimentation settler and a collection vessel disposed underneath and being in fluid communication with the sedimentation settler, the collection vessel forming a receiving chamber having an outlet at or adjacent to the chamber bottom and having an inlet opening, wherein the collection vessel is arranged such the flow direction of the fluid in the area underneath the sedimentation settler is substantially in line with the direction of the channels of the sedimentation settler.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: July 7, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Oskar Braunersreuther, Alexander Jockwer, Torsten Klabuhn, Michael Pohlscheidt, Joerg Thiele
  • Patent number: 10674720
    Abstract: An apparatus and a method for cryopreserving a plurality of cellular samples are disclosed. The apparatus may include a cooling chamber and a cooling device that may include a mechanism to cool an interior of the cooling chamber. The cooling device may further include cooling tubes that are separate from the mechanism to cool the interior of the cooling chamber and that are arranged within the cooling chamber. The cooling device may provide a flow of refrigerant through the cooling tubes and a support for supporting a plurality of vials for storing cellular samples. The support may be movable relative to the cooling tubes such that the plurality of vials may be engageable with the cooling tubes.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 9, 2020
    Assignee: HOFFMAN-LA ROCHE, INC.
    Inventors: Rüdiger Bauer, Markus Hammel, Sandra Loeder, Robert Pienkny, Clara Von Ledebur-Wicheln, Steffen Wehner
  • Publication number: 20200172589
    Abstract: In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing Calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing Calcium-ions and namely under conditions under which the erythropoietin binds to the stationary phase containing hydroxyapatite, ii) a solution is passed over the stationary phase containing hydroxyapatite from i) which contains less Calcium-ions than the previous solution and the erythropoietin is not detached from stationary phase containing hydroxyapatite, and iii) a further solution which contains less than 0.5 mM Calcium-ions is passed over the stationary phase containing hydroxyapatite from ii) whereby the erythropoietin is detached from the stationary phase containing hydroxyapatite.
    Type: Application
    Filed: October 11, 2019
    Publication date: June 4, 2020
    Applicant: Hoffman-La Roche Inc.
    Inventors: Christian SCHMALZ, Antje SCHMELZER
  • Patent number: 10654857
    Abstract: Compounds of formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: May 19, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Holger Kuehne, Patrizio Mattei, Markus Rudolph
  • Publication number: 20200147123
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: October 23, 2019
    Publication date: May 14, 2020
    Applicant: HOFFMAN-LA ROCHE INC.
    Inventors: Susanne KAMMLER, Anaïs LOPEZ, Henrik MUELLER, Søren OTTOSEN, Lykke PEDERSEN
  • Patent number: 10640472
    Abstract: The invention provides novel compounds having the general formula (I) wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: May 5, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Holger Kuehne, Thomas Luebbers, Rainer E. Martin, Patrizio Mattei, Werner Neidhart, Hans Richter, Markus Rudolph, Emmanuel Pinard
  • Patent number: 10611840
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: April 7, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Patent number: 10517945
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 31, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Joerg Benz, Ulrich Brinkmann, Stefan Dengl, Sebastian Dziadek, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann
  • Patent number: 10479796
    Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: November 19, 2019
    Assignee: Hoffman-La Roche Inc.
    Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
  • Patent number: 10457644
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: October 29, 2019
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marius Hoener, Juergen Wichmann
  • Patent number: 10344085
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 9, 2019
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • Patent number: 10287352
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 14, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick